Multipl Skleroz ve Kök Hücre Tedavisi
Özet
Referanslar
Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014;83(11):1022-4. doi: 10.1212/WNL.0000000000000768.
Nawar AA, Farid AM, Wally R, Tharwat EK, Sameh A, Elkaramany Y, Asla MM, Kamel WA. Efficacy and safety of stem cell transplantation for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2024;14(1):12545. doi: 10.1038/s41598-024-62726-4.
Genc B, Bozan HR, Genc S, Genc K. Stem Cell Therapy for Multiple Sclerosis. Adv Exp Med Biol. 2019;1084:145-174. doi: 10.1007/5584_2018_247.
Mavridi A, Bompou ME, Redmond A, Archontakis-Barakakis P, Vavougios GD, Mitsikostas DD, Mavridis T. Current and Emerging Treatment Options in Pediatric Onset Multiple Sclerosis. Sclerosis. 2024; 2(2):88-107. https://doi.org/10.3390/sclerosis2020007
Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav. 2015;5(9):e00362. doi: 10.1002/brb3.362.
Banwell B. Treatment of children and adolescents with multiple sclerosis. Expert Rev Neurother. 2005;5(3):391-401. doi: 10.1586/14737175.5.3.391.
Waldman AT, Gorman MP, Rensel MR, Austin TE, Hertz DP, Kuntz NL; Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol. 2011;26(6):675-82. doi: 10.1177/0883073810395141.
Nutma E, Willison H, Martino G, Amor S. Neuroimmunology - the past, present and future. Clin Exp Immunol. 2019;197(3):278-293. doi: 10.1111/cei.13279.
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76. doi: 10.1016/j.cell.2006.07.024. Epub 2006 Aug 10.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-72. doi: 10.1016/j.cell.2007.11.019.
Canpolat M. Pediatrik Nöroloji Hastalarında Kök Hücre Uygulamaları. In, Temel Pediatrik Nöroloji Tanı ve Tedavi (Kumandaş& Canpolat). Akademisyen Kitabevi, 2022. pp.719-746
Üstün CA, Dinç GT. Kök Hücre Bilimlerinde Güncel Tanımlar. In, Canpolat Çocuk Nörolojisi Pratiğinde Kök Hücre, Multidisipliner Yaklaşım (Editör: Canpolat M). Akademisyen Kitabevi, 2023. pp.19-30)
Baran M, Kalkan KT. Kök Hücre Çeşitleri ve Kaynakaları. In, Canpolat Çocuk Nörolojisi Pratiğinde Kök Hücre, Multidisipliner Yaklaşım (Editör: Canpolat M). Akademisyen Kitabevi, 2023. pp.47-56.
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7. doi: 10.1080/14653240600855905.
Gönen ZB, Şahin NS. Klinik kullanım için mezenkimal kök hücrelerin hazırlanması. Akd Tıp D 2019; 5(2):169-75.
Türkmen D, Canpolat M. Kök Hücre Kaynaklı Eksozomlar ve Çocuk Nörolojisi Pratiğinde Kullanımı. Kök Hücre Bilimlerinde Güncel Tanımlar. In, Canpolat Çocuk Nörolojisi Pratiğinde Kök Hücre, Multidisipliner Yaklaşım (Editör: Canpolat M). Akademisyen Kitabevi, 2023. pp.395-409)
Besnek M, Canpolat M. Kök Hücre Tedavisinde: Geçmiş, Bugün ve Gelecek. Kök Hücre Bilimlerinde Güncel Tanımlar. In, Canpolat Çocuk Nörolojisi Pratiğinde Kök Hücre, Multidisipliner Yaklaşım (Editör: Canpolat M). Akademisyen Kitabevi, 2023. pp.377-395)
Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, Tsompanakou A. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 1997;20(8):631-8. doi: 10.1038/sj.bmt.1700944.
Rice CM, Kemp K, Wilkins A, Scolding NJ. Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Lancet. 2013;382(9899):1204-13. doi: 10.1016/S0140-6736(13)61810-3.
Christodoulou MV, Petkou E, Atzemoglou N, Gkorla E, Karamitrou A, Simos YV, Bellos S, Bekiari C, Kouklis P, Konitsiotis S, Vezyraki P, Peschos D, Tsamis KI. Cell replacement therapy with stem cells in multiple sclerosis, a systematic review. Hum Cell. 2024;37(1):9-53. doi: 10.1007/s13577-023-01006-1.
Rahim F, Arjmand B, Tirdad R, Saki Malehi A. Stem cell therapy for multiple sclerosis. Cochrane Database Syst Rev. 2019 Sep 24;2019(9):CD013049. doi: 10.1002/14651858.CD013049.pub2.
Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis. Cell-based therapeutic strategies for multiple sclerosis. Brain. 2017;140(11):2776-2796. doi: 10.1093/brain/awx154.
https://dosyamerkez.saglik.gov.tr/Eklenti/15612/0/kok-hucre-calismalari-genelgepdf.pdf
Patel AA, Samia P, Singhi P, Kirton A, Hegde A, Dale R, Idro R, Cross H, Tein I, Topaloglu H and Wilmshurst J. Position statement from the Advocacy Committee of the ICNA On StemCell Therapies in Autism Spectrum Disorders and Cerebral Palsy. Journal of the International Child Neurology Association, 2022;1 (1). https://doi.org/10.17724/jicna.2023.196
Sun JM, Kurtzberg J. Stem cell therapies in cerebral palsy and autism spectrum disorder. Dev Med Child Neurol. 2021;63(5):503-510. doi: 10.1111/dmcn.14789.
Karussis D, Kassis I. The potential use of stem cells in multiple sclerosis: an overview of the preclinical experience. Clin Neurol Neurosurg. 2008;110(9):889-96. doi: 10.1016/j.clineuro.2008.02.008.
Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R, Campbell C, Memon S, Nagle JW, Hakim FT, Gress RE, McFarland HF, Burt RK, Martin R. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201(5):805-16. doi: 10.1084/jem.20041679.
Snowden JA. Rebooting autoimmunity with autologous HSCT. Blood. 2016;127(1):8-10. doi: 10.1182/blood-2015-11-678607. PMID: 26744435.
Burman J, Fransson M, Tötterman TH, Fagius J, Mangsbo SM, Loskog AS. T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis. Immunology. 2013;140(2):211-9. doi: 10.1111/imm.12129.
de Paula A Sousa A, Malmegrim KC, Panepucci RA, Brum DS, Barreira AA, Carlos Dos Santos A, Araújo AG, Covas DT, Oliveira MC, Moraes DA, Pieroni F, Barros GM, Simões BP, Nicholas R, Burt RK, Voltarelli JC, Muraro PA. Autologous haematopoietic stem cell transplantation reduces abnormalities in the expression of immune genes in multiple sclerosis. Clin Sci (Lond). 2015;128(2):111-20. doi: 10.1042/CS20140095.
Dantuma E, Merchant S, Sugaya K. Stem cells for the treatment of neurodegenerative diseases. Stem Cell Res Ther. 2010;1(5):37. doi: 10.1186/scrt37.
Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, Du MQ, Luan SL, Altmann DR, Thompson AJ, Compston A, Scott MA, Miller DH, Chandran S. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11(2):150-6. doi: 10.1016/S1474-4422(11)70305-2.
Martino G, Pluchino S. The therapeutic potential of neural stem cells. Nat Rev Neurosci. 2006;7(5):395-406. doi: 10.1038/nrn1908. PMID: 16760919.
Fossati V, Douvaras P. Generating induced pluripotent stem cells for multiple sclerosis therapy. Regen Med. 2014;9(6):709-11. doi: 10.2217/rme.14.63.
Hew M, O'Connor K, Edel MJ, Lucas M. The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases. J Clin Med. 2015;4(6):1193-206. doi: 10.3390/jcm4061193.
Xie C, Liu YQ, Guan YT, Zhang GX. Induced Stem Cells as a Novel Multiple Sclerosis Therapy. Curr Stem Cell Res Ther. 2016;11(4):313-20. doi: 10.2174/1574888x10666150302110013.
Atkins HL, Freedman MS. Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned. Neurotherapeutics. 2013;10(1):68-76. doi: 10.1007/s13311-012-0162-5.
Pandit AK, Prasad K, Seth T. Autologous hematopoietic stem cell transplantation in progressive severe multiple sclerosis. Ann Indian Acad Neurol. 2015;18(4):459-63. doi: 10.4103/0972-2327.165482.
Currò D, Mancardi G. Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience. Neurol Sci. 2016;37(6):857-65. doi: 10.1007/s10072-016-2564-3.
Makarov SV, Rossiev VA, Mishchenko OV, Kozlov VA, Semagina OV, Alexandrova IY, Grishina GV, Minaev YL. [The role and place of high-dose immunosuppressive therapy and autologous transplantation of hematopoietic stem cells for autoimmune diseases]. Ter Arkh. 2016;88(1):53-59. Russian. doi: 10.17116/terarkh201688153-59.
Sormani MP, Muraro P. Updated views on autologous hematopoietic stem cell transplantation for treatment of multiple sclerosis. Expert Rev Neurother. 2016;16(5):469-70. doi: 10.1586/14737175.2016.1158648.
Szczechowski L, Śmiłowski M, Helbig G, Krawczyk-Kuliś M, Kyrcz-Krzemień S. Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis - whom, when and how. Int J Neurosci. 2016;126(10):867-71. doi: 10.3109/00207454.2015.1121388.
Boffa G, Inglese M, Mancardi GL. Hematopoietic stem cell transplantation for multiple sclerosis. Handb Clin Neurol. 2024;202:153-167. doi: 10.1016/B978-0-323-90242-7.00011-0. PMID: 39111906.
Nabizadeh F, Pirahesh K, Rafiei N, Afrashteh F, Ahmadabad MA, Zabeti A, Mirmosayyeb O. Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis. Neurol Ther. 2022;11(4):1553-1569. doi: 10.1007/s40120-022-00389-x.
Burman J, Kirgizov K, Carlson K, Badoglio M, Mancardi GL, De Luca G, Casanova B, Ouyang J, Bembeeva R, Haas J, Bader P, Snowden J, Farge D. Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2017;52(8):1133-1137. doi: 10.1038/bmt.2017.40.
Ge F, Lin H, Li Z, Chang T. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis. Neurol Sci. 2019;40(3):479-487. doi: 10.1007/s10072-018-3670-1.
Genchi A, Brambilla E, Sangalli F, Radaelli M, Bacigaluppi M, Furlan R, Andolfo A, Drago D, Magagnotti C, Scotti GM, Greco R, Vezzulli P, Ottoboni L, Bonopane M, Capilupo D, Ruffini F, Belotti D, Cabiati B, Cesana S, Matera G, Leocani L, Martinelli V, Moiola L, Vago L, Panina-Bordignon P, Falini A, Ciceri F, Uglietti A, Sormani MP, Comi G, Battaglia MA, Rocca MA, Storelli L, Pagani E, Gaipa G, Martino G. Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study. Nat Med. 2023;29(1):75-85. doi: 10.1038/s41591-022-02097-3.
Boffa G, Signori A, Massacesi L, Mariottini A, Sbragia E, Cottone S, Amato MP, Gasperini C, Moiola L, Meletti S, Repice AM, Brescia Morra V, Salemi G, Patti F, Filippi M, De Luca G, Lus G, Zaffaroni M, Sola P, Conte A, Nistri R, Aguglia U, Granella F, Galgani S, Caniatti LM, Lugaresi A, Romano S, Iaffaldano P, Cocco E, Saccardi R, Angelucci E, Trojano M, Mancardi GL, Sormani MP, Inglese M; Italian BMT-MS Study Group and the Italian MS Register. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis. Neurology. 2023;100(11):e1109-e1122. doi: 10.1212/WNL.0000000000206750.
Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010;67(10):1187-94. doi: 10.1001/archneurol.2010.248.
Freedman MS, Uccelli A. Neurorepair with mesenchymal stem cells: hope or hype? Lancet Neurol. 2012;11(2):123-5. doi: 10.1016/S1474-4422(12)70001-7.
Llufriu S, Sepúlveda M, Blanco Y, Marín P, Moreno B, Berenguer J, Gabilondo I, Martínez-Heras E, Sola-Valls N, Arnaiz JA, Andreu EJ, Fernández B, Bullich S, Sánchez-Dalmau B, Graus F, Villoslada P, Saiz A. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One. 2014;9(12):e113936. doi: 10.1371/journal.pone.0113936.
Alanazi A, Alassiri M, Jawdat D, Almalik Y. Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis. Regen Ther. 2022;21:201-209. doi: 10.1016/j.reth.2022.07.003. PMID:
Ghareghani M, Arneaud A, Rivest S. The evolution of mesenchymal stem cell-derived neural progenitor therapy for Multiple Sclerosis: from concept to clinic. Front Cell Neurosci. 2024;18:1428652. doi: 10.3389/fncel.2024.1428652.
Finkel Z, Esteban F, Rodriguez B, Fu T, Ai X, Cai L. Diversity of Adult Neural Stem and Progenitor Cells in Physiology and Disease. Cells. 2021;10(8):2045. doi: 10.3390/cells10082045.
Zhang C, Cao J, Li X, Xu H, Wang W, Wang L, Zhao X, Li W, Jiao J, Hu B, Zhou Q, Zhao T. Treatment of multiple sclerosis by transplantation of neural stem cells derived from induced pluripotent stem cells. Sci China Life Sci. 2016;59(9):950-7. doi: 10.1007/s11427-016-0114-9.
Wang X, Kimbrel EA, Ijichi K, Paul D, Lazorchak AS, Chu J, Kouris NA, Yavanian GJ, Lu SJ, Pachter JS, Crocker SJ, Lanza R, Xu RH. Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis. Stem Cell Reports. 2014;3(1):115-30. doi: 10.1016/j.stemcr.2014.04.020. Erratum in: Stem Cell Reports. 2021 Feb 9;16(2):370-371. doi: 10.1016/j.stemcr.2021.01.004.
Aharonowiz M, Einstein O, Fainstein N, Lassmann H, Reubinoff B, Ben-Hur T. Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis. PLoS One. 2008;3(9):e3145. doi: 10.1371/journal.pone.0003145.
Shroff G. Transplantation of Human Embryonic Stem Cells in Patients with Multiple Sclerosis and Lyme Disease. Am J Case Rep. 2016;17:944-949. doi: 10.12659/ajcr.899745.
Harris VK, Vyshkina T, Sadiq SA. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis. Cytotherapy. 2016;18(12):1476-1482. doi: 10.1016/j.jcyt.2016.08.007.
Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, Herlopian A, Baz EK, Mahfouz R, Khalil-Hamdan R, Kreidieh NM, El-Sabban M, Bazarbachi A. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol. 2010;227(1-2):185-9. doi: 10.1016/j.jneuroim.2010.07.013.
Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, Alimoghaddom K, Talebian F, Hooshmand F, Ghavamzadeh A, Nikbin B. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol. 2007;4(1):50-7. PMID: 17652844.
Castelo-Branco A, Chiesa F, Conte S, Bengtsson C, Lee S, Minton N, Niemcryk S, Lindholm A, Rosenlund M, Piehl F, Montgomery S. Infections in patients with multiple sclerosis: A national cohort study in Sweden. Mult Scler Relat Disord. 2020;45:102420. doi: 10.1016/j.msard.2020.102420.
Kishk NA, Abokrysha NT, Gabr H. Possible induction of acute disseminated encephalomyelitis (ADEM)-like demyelinating illness by intrathecal mesenchymal stem cell injection. J Clin Neurosci. 2013;20(2):310-2. doi: 10.1016/j.jocn.2012.04.013.
Alderazi YJ, Coons SW, Chapman K. Catastrophic demyelinating encephalomyelitis after intrathecal and intravenous stem cell transplantation in a patient with multiple sclerosis. J Child Neurol. 2012;27(5):632-5. doi: 10.1177/0883073811422831.
Palacio PL, Pleet ML, Reátegui E, Magaña SM. Emerging role of extracellular vesicles in multiple sclerosis: From cellular surrogates to pathogenic mediators and beyond. J Neuroimmunol. 2023;377:578064. doi: 10.1016/j.jneuroim.2023.578064.
Mrad MF, Saba ES, Nakib L, Khoury SJ. Exosomes From Subjects With Multiple Sclerosis Express EBV-Derived Proteins and Activate Monocyte-Derived Macrophages. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1004. doi: 10.1212/NXI.0000000000001004.
Kråkenes T, Sandvik CE, Ytterdal M, Gavasso S, Evjenth EC, Bø L, Kvistad CE. The Therapeutic Potential of Exosomes from Mesenchymal Stem Cells in Multiple Sclerosis. Int J Mol Sci. 2024;25(19):10292. doi: 10.3390/ijms251910292.
Barabadi M, Paton MCB, Kumar N, Lim R, Payne NL. Stem Cell Derived Extracellular Vesicle Therapy for Multiple Sclerosis, A Systematic Review and Meta-Analysis of Preclinical Studies. Stem Cells Transl Med. 2024;13(5):436-447. doi: 10.1093/stcltm/szae011.
Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3-S9. doi: 10.1002/ajh.25418.
Rankin AW, Shah NN. CD19 CAR T cells for multiple sclerosis: Forging further into the new frontier. Med. 2024;5(6):482-484. doi: 10.1016/j.medj.2024.04.005.
Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach RG, Schäfer S, Grieshaber-Bouyer R, Korganow AS, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Krönke G, Mackensen A, Schett G. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med. 2024;390(8):687-700. doi: 10.1056/NEJMoa2308917.
Fischbach F, Richter J, Pfeffer LK, Fehse B, Berger SC, Reinhardt S, Kuhle J, Badbaran A, Rathje K, Gagelmann N, Borie D, Seibel J, Ayuk F, Friese MA, Heesen C, Kröger N. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024;5(6):550-558.e2. doi: 10.1016/j.medj.2024.03.002.
Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D, Greco R, Jessop H, Kazmi M, Kirgizov K, Labopin M, Mancardi G, Martin R, Moore J, Muraro PA, Rovira M, Sormani MP, Snowden JA; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE). Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant. 2020;55(2):283-306. doi: 10.1038/s41409-019-0684-0.
Zeng L, Yu G, Yang K, Xiang W, Li J, Chen H. Efficacy and Safety of Mesenchymal Stem Cell Transplantation in the Treatment of Autoimmune Diseases (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease, Multiple Sclerosis, and Ankylosing Spondylitis): A Systematic Review and Meta-Analysis of Randomized Controlled Trial. Stem Cells Int. 2022;2022:9463314. doi: 10.1155/2022/9463314.
Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, Denton C, Hawkey C, Labopin M, Mancardi G, Martin R, Moore JJ, Passweg J, Peters C, Rabusin M, Rovira M, van Laar JM, Farge D; EBMT Autoimmune Disease Working Party (ADWP); Paediatric Diseases Working Party (PDWP). Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012;47(6):770-90. doi: 10.1038/bmt.2011.185.
Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol. 2017;13(7):391-405. doi: 10.1038/nrneurol.2017.81.
Başar E, Demir GA. Multipl Sklerozda Kök Hücre Tedavisi. İn, Multipl Skleroz Tanı Ve Tedavi Kılavuzu 2018, ( Editörler; Efendi S, Kuşcu DY). Galenos Yayınevi, İstanbul, 2018. pp:130-31
Wu L, Lu J, Lan T, Zhang D, Xu H, Kang Z, Peng F, Wang J. Stem cell therapies: a new era in the treatment of multiple sclerosis. Front Neurol. 2024;15:1389697. doi: 10.3389/fneur.2024.1389697.
Öz Dağdelen Z, Perk P, Canpolat M, Nöroimmunoloji Pratiğinde Kök Hücre Kullanımı. Canpolat Temel Pediatrik Nöroimmünoloji (Editör; Canpolat M), Akademisyen Kitabevi, 2025. pp:..
